WideMed Ltd. (TASE:WDMD) today reported success in a clinical trial of its Morpheu automated device for monitoring and documenting sleep apnea and cardiology variables.
The study found that documentation by the system was as good as manual monitoring from visual viewing of patients and monitors. In the notice to the Tel Aviv Stock Exchange (TASE), WideMed cautioned that this was its first important announcement, besides its financial reports, so far this year about the company's activities. [...]
WideMed's sleep apnea monitor was able, among other things, to distinguish between awake and sleep states, identify and classify sleep apnea events, and identify cardiology events. The study results were submitted to the US Food and Drug Administration (FDA) in order to obtain marketing approval for Morpheus for this purpose. WideMed already has FDA clearance for the diagnosis of sleep apnea and cardiology events in intensive care units, and the company signed a marketing agreement with GE Healthcare two years ago. In its financial report for the first quarter, WideMed said that joint marketing of Morpheus would begin in a few months.
Lire l'intégralité de l'article » (Source: article de Gali Weinreb @ Globes)
Antibcott Israel blog apnée du sommeil, cardiologie